June 9, 2022 03:18 PM EDTUpdated June 23, 02:20 PM

#BIO22: The bear market may be mauling biotech stocks, but the fundamentals still look good to real estate developers

Sarah Cohen

Contributor

The bear market that has cut the valuations of biotech companies has not yet affected real estate development in life sciences, which continues to experience …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

#BIO22: The bear market may be mauling biotech stocks, but the fundamentals still look good to real estate developers

Sarah Cohen

Contributor

Sign up to read this article for free.

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

Food allergy biotech Alladapt closes after Phase 3 talks with FDA

#BIO22: The bear mar­ket may be maul­ing biotech stocks, but the fun­da­men­tals still look good to re­al es­tate de­vel­op­ers

Sarah Cohen

Contributor

Sign up to read this article for free.

more like this

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

#BIO22: The bear market may be mauling biotech stocks, but the fundamentals still look good to real estate developers

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

Food allergy biotech Alladapt closes after Phase 3 talks with FDA